Literature DB >> 17228067

Underuse of revascularisation in acute coronary syndromes.

Franz-Josef Neumann, Heinz Joachim Büttner.   

Abstract

Is coronary revascularisation being underused in patients at highest risk, and overused in those at lower risk?

Entities:  

Mesh：

Year:  2007        PMID： 17228067      PMCID： PMC1861406          DOI： 10.1136/hrt.2006.092643

Source DB:  PubMed          Journal:  Heart        ISSN： 1355-6037            Impact factor:   5.994


  13 in total

1.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation.

Authors:  Michel E Bertrand; Maarten L Simoons; Keith A A Fox; Lars C Wallentin; Christian W Hamm; Eugene McFadden; Pim J De Feyter; Giuseppe Specchia; Witold Ruzyllo
Journal:  Eur Heart J       Date:  2002-12       Impact factor: 29.983

2.  Intervention in acute coronary syndromes: do patients undergo intervention on the basis of their risk characteristics? The Global Registry of Acute Coronary Events (GRACE).

Authors:  K A A Fox; F A Anderson; O H Dabbous; P G Steg; J López-Sendón; F Van de Werf; A Budaj; E P Gurfinkel; S G Goodman; D Brieger
Journal:  Heart       Date:  2006-06-06       Impact factor: 5.994

Review 3.  Comparison of mortality rates in acute myocardial infarction treated by percutaneous coronary intervention versus fibrinolysis.

Authors:  Amadeo Betriu; Mónica Masotti
Journal:  Am J Cardiol       Date:  2005-01-01       Impact factor: 2.778

4.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.

Authors:  C P Cannon; W S Weintraub; L A Demopoulos; R Vicari; M J Frey; N Lakkis; F J Neumann; D H Robertson; P T DeLucca; P M DiBattiste; C M Gibson; E Braunwald
Journal:  N Engl J Med       Date:  2001-06-21       Impact factor: 91.245

5.  Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients.

Authors:  Christian Mueller; Heinz J Buettner; John M Hodgson; Stephan Marsch; André P Perruchoud; Helmut Roskamm; Franz-Josef Neumann
Journal:  Circulation       Date:  2002-03-26       Impact factor: 29.690

6.  Clinical outcomes, risk stratification and practice patterns of unstable angina and myocardial infarction without ST elevation: Prospective Registry of Acute Ischaemic Syndromes in the UK (PRAIS-UK)

Authors:  J Collinson; M D Flather; K A Fox; I Findlay; E Rodrigues; P Dooley; P Ludman; J Adgey; T J Bowker; R Mattu
Journal:  Eur Heart J       Date:  2000-09       Impact factor: 29.983

7.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast Revascularisation during InStability in Coronary artery disease Investigators.

Authors: 
Journal:  Lancet       Date:  1999-08-28       Impact factor: 79.321

8.  Evaluation of prolonged antithrombotic pretreatment ("cooling-off" strategy) before intervention in patients with unstable coronary syndromes: a randomized controlled trial.

Authors:  Franz-Josef Neumann; Adnan Kastrati; Gisela Pogatsa-Murray; Julinda Mehilli; Hildegard Bollwein; Hans-Peter Bestehorn; Claus Schmitt; Melchior Seyfarth; Josef Dirschinger; Albert Schömig
Journal:  JAMA       Date:  2003-09-24       Impact factor: 56.272

Review 9.  Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Authors:  Ellen C Keeley; Judith A Boura; Cindy L Grines
Journal:  Lancet       Date:  2003-01-04       Impact factor: 79.321

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.